ProShare Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-10,681
| Closed | -$159K | – | 2355 |
|
|
2021
Q3 | $159K | Sell |
10,681
-2,546
| -19% | -$40.7K | ﹤0.01% | 1837 |
|
|
2021
Q2 | $264K | Buy |
13,227
+1,730
| +15% | +$34.3K | ﹤0.01% | 1974 |
|
|
2021
Q1 | $265K | Buy |
11,497
+663
| +6% | +$18.5K | ﹤0.01% | 1870 |
|
|
2020
Q4 | $268K | Buy |
10,834
+2,341
| +28% | +$77.6K | ﹤0.01% | 1682 |
|
|
2020
Q3 | $352K | Sell |
8,493
-708
| -8% | -$32.5K | ﹤0.01% | 1092 |
|
|
2020
Q2 | $441K | Buy |
9,201
+2,767
| +43% | +$214K | ﹤0.01% | 1013 |
|
|
2020
Q1 | $405K | Sell |
6,434
-4,657
| -42% | -$419K | ﹤0.01% | 783 |
|
|
2019
Q4 | $1.37M | Sell |
11,091
-1,217
| -10% | -$109K | 0.01% | 707 |
|
|
2019
Q3 | $817K | Sell |
12,308
-116
| -0.9% | -$7.79K | ﹤0.01% | 823 |
|
|
2019
Q2 | $989K | Sell |
12,424
-907
| -7% | -$81.2K | 0.01% | 761 |
|
|
2019
Q1 | $1.49M | Buy |
13,331
+326
| +3% | +$35.6K | 0.01% | 660 |
|
|
2018
Q4 | $1.31M | Sell |
13,005
-2,502
| -16% | -$259K | 0.01% | 655 |
|
|
2018
Q3 | $1.96M | Sell |
15,507
-309
| -2% | -$32.7K | 0.01% | 611 |
|
|
2018
Q2 | $1.33M | Buy |
15,816
+3,724
| +31% | +$273K | 0.01% | 736 |
|
|
2018
Q1 | $744K | Sell |
12,092
-1,912
| -14% | -$115K | ﹤0.01% | 942 |
|
|
2017
Q4 | $818K | Sell |
14,004
-558
| -4% | -$35.2K | 0.01% | 918 |
|
|
2017
Q3 | $845K | Buy |
14,562
+1,353
| +10% | +$146K | 0.01% | 773 |
|
|
2017
Q2 | $1.6M | Sell |
13,209
-407
| -3% | -$47.1K | 0.02% | 611 |
|
|
2017
Q1 | $1.54M | Sell |
13,616
-3,026
| -18% | -$353K | 0.02% | 625 |
|
|
2016
Q4 | $1.81M | Buy |
16,642
+473
| +3% | +$56.3K | 0.02% | 578 |
|
|
2016
Q3 | $2.66M | Sell |
16,169
-2,721
| -14% | -$429K | 0.04% | 413 |
|
|
2016
Q2 | $2.69M | Buy |
18,890
+451
| +2% | +$65.8K | 0.03% | 398 |
|
|
2016
Q1 | $2.37M | Sell |
18,439
-1,774
| -9% | -$209K | 0.03% | 401 |
|
|
2015
Q4 | $3.02M | Buy |
20,213
+1,130
| +6% | +$191K | 0.04% | 393 |
|
|
2015
Q3 | $3.17M | Sell |
19,083
-900
| -5% | -$198K | 0.04% | 353 |
|
|
2015
Q2 | $4.82M | Buy |
19,983
+1,252
| +7% | +$333K | 0.07% | 274 |
|
|
2015
Q1 | $5.28M | Buy |
18,731
+4,022
| +27% | +$871K | 0.06% | 303 |
|
|
2014
Q4 | $2.29M | Buy |
+14,709
| New | +$2.72M | 0.03% | 529 |
|
|
2014
Q2 | – | Sell |
-7,270
| Closed | -$2.4M | – | 2650 |
|
|
2014
Q1 | $2.4M | Buy |
+7,270
| New | +$2.45M | 0.03% | 642 |
|
|
2013
Q4 | – | Sell |
-4,528
| Closed | -$313K | – | 1957 |
|
|
2013
Q3 | $313K | Buy |
+4,528
| New | +$224K | 0.01% | 1873 |
|
Other funds holding ICPT
SB
ProShare Advisors's ICPT Position: Q4 2021 in Review
ProShare Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 10,681 shares — an estimated $159K sold.
ProShare Advisors first reported a position in ICPT in Q3 2013 and held it in 30 quarters. The position peaked at $5.28M in Q1 2015. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.
- ProShare Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- ProShare Advisors sold 10,681 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $159K.
- ProShare Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 30 quarters.
- ProShare Advisors's Intercept Pharmaceuticals, Inc. position peaked at $5.28M in Q1 2015.
- 147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.
Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.